Literature DB >> 23182191

TAS-102: more than an antimetabolite.

Godefridus J Peters, Irene V Bijnsdorp.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23182191     DOI: 10.1016/S1470-2045(12)70426-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

Review 1.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

2.  Trifluridine/Tipiracil (Lonsurf) for the Treatment of Metastatic Colorectal Cancer.

Authors:  Troy Kish; Priyasha Uppal
Journal:  P T       Date:  2016-05

Review 3.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

4.  Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro.

Authors:  I V Bijnsdorp; Godefridus J Peters
Journal:  Cancer Drug Resist       Date:  2021-05-24

5.  Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis.

Authors:  Duke Chen; Yu-Shen Wu; Huapeng Lin; Yihan Wang; Longhao Li; Tao Zhang
Journal:  Cancer Manag Res       Date:  2018-08-28       Impact factor: 3.989

Review 6.  Biomarkers of Trifluridine-Tipiracil Efficacy.

Authors:  Ioannis A Voutsadakis
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

7.  Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity.

Authors:  Ankush Paladhi; Samrat Daripa; Indrani Mondal; Sumit Kumar Hira
Journal:  Front Immunol       Date:  2022-08-24       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.